These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2008-002109-38 A Phase 1b/2a, Open-Label, Multi-Center Study of AV-951 in Combination with Paclitaxel in Subjects with Advanced or Metastatic Breast Cancer 2011-01-07 due-trials
Listed as ongoing, but also has a completion date 2009-013219-37 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma 2013-06-10 bad-data
Listed as ongoing, but also has a completion date 2009-013407-66 A Rollover Protocol to allow continued access to Tivozanib (AV-951) for subjects enrolled in other Tivozanib Protocols 2015-06-23 bad-data
Listed as ongoing, but also has a completion date 2009-015987-32 An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib Hydrochloride vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301) 2015-02-24 bad-data
Listed as ongoing, but also has a completion date 2012-001730-33 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CROSSOVER, CONTROLLED, MULTI-CENTER, SUBJECT PREFERENCE STUDY OF TIVOZANIB HYDROCHLORIDE VERSUS SUNITINIB IN THE TREATMENT OF SUBJECTS WITH METASTATIC RENAL CELL CA... 2013-09-18 bad-data
Not reported 2012-003507-35 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the ... 2014-02-03 due-trials
Other 2014-003443-35 A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lu... not-yet-due
Ongoing 2015-003607-30 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma not-yet-due